From: Strategies for ocular siRNA delivery: Potential and limitations of non-viral nanocarriers
Company | Drug Name | siRNA target | Carrier | Disease | Delivery method | Clinical status | Reference |
---|---|---|---|---|---|---|---|
Silence Therapeutics/ Quark/Pfizer | PF-655 (formerly REDD14NP and RTP801i) | RTP801/ DNA-damage- inducible transcript 4 gene (DDIT4) | Naked siRNA | AMD | Intravitreal injection | Phase II – completed | |
Silence Therapeutics/ Quark/Pfizer | PF-655 (formerly REDD14NP and RTP801i) | RTP801/DNA- damage-inducible transcript 4 gene (DDIT4) | Naked siRNA | DME | Intravitreal injection | Phase II – terminated | |
Allergan/Sirna | AGN211745 (Sirna-027) | VEGFR1 | Naked siRNA | AMD | Intravitreal injection | Phase II- terminated | |
Opko Health | Bevasiranib | VEGF | Naked siRNA | Wet AMD | Intravitreal injection | Phase III-terminated | (OpkoHealth 2011[49]) |
Sylentis | SYL040012 | ADRB2 | Naked siRNA | Glaucoma, Ocular hypertension | Topical | Phase I-completed | (Sylentis 2010[54]) |
Quark | QPI-1007 | Caspase 2 | Naked siRNA | Non-arteritic ischemic optic neuropathy (NAION), Chronic optic nerve atropy, Glaucoma | Intravitreal injection | Phase I – on going | (Quark Pharmaceuticals 2011b[53]) |